PI3K/Akt/mTOR

You can also try the following methods, and our professionals will serve you Customized Consultation

Cat. No.	Product Name	Field of Application
DC7348	3-Methyladenine Featured	3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM.
DC11929	ME-344	A novel mitochondrial and mTOR inhibitor with potent anti-cancer activity, inhibits leukemia cell lines with IC50 of 70-260 nM.
DC11968	OSU-03013	A novel potent, orally active 3-phosphoinositide-dependent kinase-1 (PDK-1) with IC50 of 2 uM.
DC11599	PF-739	A novel potent, pan-AMPK activator with similar potency for all AMPK heterotrimers.
DC11631	INCB040093	A novel potent, selective, orally available PI3Kδ inhibitor with IC50 of 31 nM.
DC11795	BL-140	A novel specific p110β inhibitor with IC50 of 5.74 nM.
DC10646	VPS34 inhibitor(Compound 80) Featured	A novel VPS34 inhibitor.
DC11938	IPI-3063	A novel, potent, and selective p110δ PI3K inhibitor with IC50 of 0.1 nM in cell-based assays.
DC11656	AMPK-Activator-13	A potent, allosteric, α1-selective small molecule activator of AMPK (EC50=20 nM).
DC11866	AZD 3147 Featured	A potent, selective dual mTORC1 and mTORC2 inhibitor with enzyme IC50 of 1.5 nM.
DC11841	LAS191954	A potent, selective, orally bioavailable PI3Kδ inhibitor with IC50 of 2.6 nM.
DC7538	A66 Featured	A66 is a potent and specific p110α inhibitor with IC50 of 32 nM, >100 fold selectivity for p110α over other class-I PI3K isoforms.
DC5163	A-674563 Featured	A-674563 is a potent, orally available Akt1 inhibitor with an IC50 value of 11nM. Also displays activity against PKA and CDK2 with IC50 values of 16nM and 46nM respectively.
DC7045	A-769662 Featured	A-769662 is a potent, reversible AMPK activator with EC50 of 0.8 μM, little effect on GPPase/FBPase activity.
DC7047	AICAR (Acadesine) Featured	Acadesine results in accumulation of ZMP, which mimics the stimulating effect of AMP on AMPK and AMPK kinase. Phase 3.
DC8760	Acalisib Featured	Acalisib (GS-9820) is a potent and selective inhibitor of PI3Kδ with IC50 value of 12.7 nM.
DC7994	Afuresertib HCl Featured	Afuresertib (GSK2110183) is a potent pan-AKT inhibitor that demonstrated synergy with bortezomib in preclinical models of multiple myeloma (MM).
DC8411	Afuresertib Featured	Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.
DC8458	Akt Inhibitor VIII Featured	Akt Inhibitor VIII is a cell-permeable quinoxaline compound that has been shown to potently, selectively, allosterically, and reversibly inhibit Akt1, Akt2, and Akt3 activity (IC50 = 58 nM, 210 nM, and 2.12 μM; respectively).
DC8695	Akt1 and Akt2-IN-1	Akt1 and Akt2-IN-1 is an allosteric inhibitor of Akt1 (IC50 = 3.5 nM) and Akt2 (IC50 = 42 nM), with potent and balanced activity.
DC8618	AMG-319 Featured	AMG 319 is an investigational, highly selective, small molecule inhibitor of PI3Kδ that blocks B cell proliferation following BCR stimulation both in vitro and in vivo, inhibits basal AKT phosphorylation, and inhibits proliferation in lymphoid tumor cells
DC11130	AMPK activator 991	AMPK activator 991 is an allosteric AMPK activator, activates non-phosphorylated Thr172 AMPK in vitro binds to α1β1γ1 and α2β1γ1 with Kd of 0.13 and 0.17 uM, respectively..
DC11129	AMPK activator SC4 Featured	AMPK activator SC4 is a highly specific and potent activator of the α2β2-AMPK complexes, which are the predominant AMPK isoform complexes found in human skeletal muscle. SC4 demonstrates significant efficacy with EC50 values of 17.2 nM for the α2β2γ1 complex and 82.1 nM for the α2β2γ3 complex. These low EC50 values indicate that SC4 is effective at relatively low concentrations, making it a promising compound for targeting AMPK in skeletal muscle. This specificity and potency suggest potential therapeutic applications in conditions where AMPK activation is beneficial, such as metabolic disorders, muscle function, and energy homeostasis.
DC1001	FK-506 (Tacrolimus) Featured	Tacrolimus (FK506), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties.
DC8275	Apilimod Featured	Apilimod(STA 5326) is a potent IL-12/IL-23 inhibitor, IL-12 production in cultures of IFN-r/LPS–stimulated human PBMCs is strongly inhibited by STA-5326 with an IC50 of 10 nM.
DC7922	APY0201 Featured	APY0201 is a potent, highly selective PIKfyve kinase inhibitor.
DC9972	ARQ-092(Miransertib) Featured	ARQ 092 is an oral activie, potent and selective AKT inhibitor with IC50 values: 5.0 nM (AKT1); 4.5 nM (AKT2); 16 nM (AKT3).
DC7068	AS605240	AS-605240 is a potent and selective inhibitor of PI 3-kinase γ (PI3Kγ) (IC50 = 8 nM). AS-605240 displays 30-fold selectivity over PI3Kδ and PI3Kβ and 7.5-fold selectivity over PI3Kα.
DC9336	AT7867 (dihydrochloride)	AT7867 Hcl is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively; little activity outside the AGC kinase family.
DC9335	AT7867 Featured	AT7867 is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively; little activity outside the AGC kinase family.

PI3K/Akt/mTOR

Customized Consultation X

Your information is safe with us. * Required Fields.